nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimetrexate—DHFR—Fluoropyrimidine Activity—SLC29A1—pancreatic cancer	0.0431	0.14	CbGpPWpGaD
Trimetrexate—Trimethoprim—TYMS—pancreatic cancer	0.0279	1	CrCbGaD
Trimetrexate—DHFR—Fluoropyrimidine Activity—TYMP—pancreatic cancer	0.0216	0.0701	CbGpPWpGaD
Trimetrexate—Electrolyte imbalance—Irinotecan—pancreatic cancer	0.0208	0.0313	CcSEcCtD
Trimetrexate—DHFR—Fluoropyrimidine Activity—DPYD—pancreatic cancer	0.0172	0.0556	CbGpPWpGaD
Trimetrexate—DHFR—G1/S-Specific Transcription—TYMS—pancreatic cancer	0.0166	0.0539	CbGpPWpGaD
Trimetrexate—Hepatotoxicity—Tamoxifen—pancreatic cancer	0.0159	0.024	CcSEcCtD
Trimetrexate—Hepatotoxicity—Erlotinib—pancreatic cancer	0.0158	0.0237	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—RBBP8—pancreatic cancer	0.0143	0.0465	CbGpPWpGaD
Trimetrexate—Serum creatinine increased—Irinotecan—pancreatic cancer	0.0141	0.0212	CcSEcCtD
Trimetrexate—Hepatotoxicity—Sunitinib—pancreatic cancer	0.0136	0.0205	CcSEcCtD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PRSS1—pancreatic cancer	0.0131	0.0426	CbGpPWpGaD
Trimetrexate—Blood bilirubin increased—Tamoxifen—pancreatic cancer	0.013	0.0196	CcSEcCtD
Trimetrexate—Hypocalcaemia—Sunitinib—pancreatic cancer	0.0115	0.0173	CcSEcCtD
Trimetrexate—DHFR—One Carbon Metabolism—TYMS—pancreatic cancer	0.0111	0.0361	CbGpPWpGaD
Trimetrexate—Blood bilirubin increased—Sunitinib—pancreatic cancer	0.0111	0.0168	CcSEcCtD
Trimetrexate—Hepatotoxicity—Gemcitabine—pancreatic cancer	0.0109	0.0165	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Sunitinib—pancreatic cancer	0.0105	0.0159	CcSEcCtD
Trimetrexate—DHFR—Trans-sulfuration and one carbon metabolism—TYMS—pancreatic cancer	0.01	0.0325	CbGpPWpGaD
Trimetrexate—DHFR—Fluoropyrimidine Activity—TYMS—pancreatic cancer	0.00978	0.0317	CbGpPWpGaD
Trimetrexate—DHFR—E2F mediated regulation of DNA replication—TYMS—pancreatic cancer	0.00978	0.0317	CbGpPWpGaD
Trimetrexate—Hypocalcaemia—Gemcitabine—pancreatic cancer	0.00923	0.0139	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Irinotecan—pancreatic cancer	0.00917	0.0138	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Gemcitabine—pancreatic cancer	0.00893	0.0135	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Sunitinib—pancreatic cancer	0.00879	0.0132	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Irinotecan—pancreatic cancer	0.00867	0.0131	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Gemcitabine—pancreatic cancer	0.00845	0.0127	CcSEcCtD
Trimetrexate—Blood creatinine increased—Tamoxifen—pancreatic cancer	0.00836	0.0126	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Tamoxifen—pancreatic cancer	0.00804	0.0121	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Tamoxifen—pancreatic cancer	0.00787	0.0119	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Erlotinib—pancreatic cancer	0.00779	0.0117	CcSEcCtD
Trimetrexate—Hepatotoxicity—Docetaxel—pancreatic cancer	0.00776	0.0117	CcSEcCtD
Trimetrexate—Hyponatraemia—Sunitinib—pancreatic cancer	0.00767	0.0116	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Irinotecan—pancreatic cancer	0.00724	0.0109	CcSEcCtD
Trimetrexate—Neutropenia—Tamoxifen—pancreatic cancer	0.00721	0.0109	CcSEcCtD
Trimetrexate—Blood creatinine increased—Sunitinib—pancreatic cancer	0.00716	0.0108	CcSEcCtD
Trimetrexate—Neutropenia—Erlotinib—pancreatic cancer	0.00714	0.0108	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Gemcitabine—pancreatic cancer	0.00705	0.0106	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Sunitinib—pancreatic cancer	0.00688	0.0104	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Sunitinib—pancreatic cancer	0.00674	0.0102	CcSEcCtD
Trimetrexate—DHFR—E2F mediated regulation of DNA replication—RB1—pancreatic cancer	0.00663	0.0215	CbGpPWpGaD
Trimetrexate—Serum creatinine increased—Epirubicin—pancreatic cancer	0.00657	0.00991	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Docetaxel—pancreatic cancer	0.00634	0.00955	CcSEcCtD
Trimetrexate—Hyponatraemia—Irinotecan—pancreatic cancer	0.00632	0.00953	CcSEcCtD
Trimetrexate—Neutropenia—Sunitinib—pancreatic cancer	0.00618	0.00931	CcSEcCtD
Trimetrexate—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—pancreatic cancer	0.00615	0.0199	CbGpPWpGaD
Trimetrexate—Serum creatinine increased—Doxorubicin—pancreatic cancer	0.00608	0.00917	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Docetaxel—pancreatic cancer	0.006	0.00903	CcSEcCtD
Trimetrexate—Blood creatinine increased—Irinotecan—pancreatic cancer	0.0059	0.00889	CcSEcCtD
Trimetrexate—Blood creatinine increased—Gemcitabine—pancreatic cancer	0.00574	0.00866	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Irinotecan—pancreatic cancer	0.00567	0.00854	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—SYCP1—pancreatic cancer	0.00562	0.0182	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—SOD2—pancreatic cancer	0.00557	0.0181	CbGpPWpGaD
Trimetrexate—Aspartate aminotransferase increased—Gemcitabine—pancreatic cancer	0.00552	0.00832	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Gemcitabine—pancreatic cancer	0.00541	0.00815	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—TYMS—pancreatic cancer	0.00518	0.0168	CbGpPWpGaD
Trimetrexate—Neutropenia—Irinotecan—pancreatic cancer	0.00509	0.00767	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Docetaxel—pancreatic cancer	0.005	0.00754	CcSEcCtD
Trimetrexate—Anaemia—Tamoxifen—pancreatic cancer	0.00497	0.00748	CcSEcCtD
Trimetrexate—Neutropenia—Gemcitabine—pancreatic cancer	0.00496	0.00747	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—TYMS—pancreatic cancer	0.0045	0.0146	CbGpPWpGaD
Trimetrexate—Hypocalcaemia—Epirubicin—pancreatic cancer	0.00442	0.00666	CcSEcCtD
Trimetrexate—Hyponatraemia—Docetaxel—pancreatic cancer	0.00437	0.00658	CcSEcCtD
Trimetrexate—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.00429	0.00647	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Epirubicin—pancreatic cancer	0.00428	0.00644	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—PLAU—pancreatic cancer	0.00427	0.0139	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism of nitric oxide—AKT1—pancreatic cancer	0.00426	0.0138	CbGpPWpGaD
Trimetrexate—Anaemia—Sunitinib—pancreatic cancer	0.00425	0.00641	CcSEcCtD
Trimetrexate—Thrombocytopenia—Erlotinib—pancreatic cancer	0.00425	0.0064	CcSEcCtD
Trimetrexate—Hypocalcaemia—Doxorubicin—pancreatic cancer	0.00409	0.00616	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Epirubicin—pancreatic cancer	0.00404	0.00609	CcSEcCtD
Trimetrexate—Convulsion—Sunitinib—pancreatic cancer	0.00399	0.00601	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Doxorubicin—pancreatic cancer	0.00396	0.00596	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Docetaxel—pancreatic cancer	0.00392	0.00591	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Docetaxel—pancreatic cancer	0.00384	0.00578	CcSEcCtD
Trimetrexate—Fatigue—Tamoxifen—pancreatic cancer	0.00378	0.0057	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—TYMS—pancreatic cancer	0.00376	0.0122	CbGpPWpGaD
Trimetrexate—Phosphatase alkaline increased—Doxorubicin—pancreatic cancer	0.00374	0.00564	CcSEcCtD
Trimetrexate—Fatigue—Erlotinib—pancreatic cancer	0.00374	0.00564	CcSEcCtD
Trimetrexate—Thrombocytopenia—Sunitinib—pancreatic cancer	0.00368	0.00554	CcSEcCtD
Trimetrexate—Neutropenia—Docetaxel—pancreatic cancer	0.00352	0.0053	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—RB1—pancreatic cancer	0.00351	0.0114	CbGpPWpGaD
Trimetrexate—Anaemia—Irinotecan—pancreatic cancer	0.0035	0.00528	CcSEcCtD
Trimetrexate—Body temperature increased—Erlotinib—pancreatic cancer	0.00343	0.00517	CcSEcCtD
Trimetrexate—Anaemia—Gemcitabine—pancreatic cancer	0.00341	0.00514	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Epirubicin—pancreatic cancer	0.00337	0.00509	CcSEcCtD
Trimetrexate—Anaemia—Fluorouracil—pancreatic cancer	0.00336	0.00506	CcSEcCtD
Trimetrexate—DHFR—Fluoropyrimidine Activity—TP53—pancreatic cancer	0.00324	0.0105	CbGpPWpGaD
Trimetrexate—Fatigue—Sunitinib—pancreatic cancer	0.00324	0.00488	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—TYMS—pancreatic cancer	0.00317	0.0103	CbGpPWpGaD
Trimetrexate—Asthenia—Tamoxifen—pancreatic cancer	0.00315	0.00474	CcSEcCtD
Trimetrexate—Convulsion—Fluorouracil—pancreatic cancer	0.00315	0.00474	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Doxorubicin—pancreatic cancer	0.00312	0.00471	CcSEcCtD
Trimetrexate—Confusional state—Irinotecan—pancreatic cancer	0.00312	0.0047	CcSEcCtD
Trimetrexate—Asthenia—Erlotinib—pancreatic cancer	0.00311	0.00469	CcSEcCtD
Trimetrexate—Pruritus—Tamoxifen—pancreatic cancer	0.0031	0.00468	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CDKN2A—pancreatic cancer	0.00309	0.01	CbGpPWpGaD
Trimetrexate—Pruritus—Erlotinib—pancreatic cancer	0.00307	0.00463	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—RB1—pancreatic cancer	0.00305	0.00989	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00303	0.00457	CcSEcCtD
Trimetrexate—Confusional state—Fluorouracil—pancreatic cancer	0.00299	0.0045	CcSEcCtD
Trimetrexate—Body temperature increased—Sunitinib—pancreatic cancer	0.00297	0.00447	CcSEcCtD
Trimetrexate—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.00295	0.00445	CcSEcCtD
Trimetrexate—Hyponatraemia—Epirubicin—pancreatic cancer	0.00295	0.00444	CcSEcCtD
Trimetrexate—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.0029	0.00437	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—RBBP8—pancreatic cancer	0.00288	0.00932	CbGpPWpGaD
Trimetrexate—Vomiting—Tamoxifen—pancreatic cancer	0.00279	0.0042	CcSEcCtD
Trimetrexate—Rash—Tamoxifen—pancreatic cancer	0.00277	0.00417	CcSEcCtD
Trimetrexate—Dermatitis—Tamoxifen—pancreatic cancer	0.00276	0.00416	CcSEcCtD
Trimetrexate—Vomiting—Erlotinib—pancreatic cancer	0.00276	0.00416	CcSEcCtD
Trimetrexate—Blood creatinine increased—Epirubicin—pancreatic cancer	0.00275	0.00414	CcSEcCtD
Trimetrexate—Rash—Erlotinib—pancreatic cancer	0.00274	0.00412	CcSEcCtD
Trimetrexate—Dermatitis—Erlotinib—pancreatic cancer	0.00273	0.00412	CcSEcCtD
Trimetrexate—Hyponatraemia—Doxorubicin—pancreatic cancer	0.00273	0.00411	CcSEcCtD
Trimetrexate—Asthenia—Sunitinib—pancreatic cancer	0.0027	0.00406	CcSEcCtD
Trimetrexate—Fatigue—Irinotecan—pancreatic cancer	0.00267	0.00402	CcSEcCtD
Trimetrexate—Pruritus—Sunitinib—pancreatic cancer	0.00266	0.004	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.00264	0.00398	CcSEcCtD
Trimetrexate—Nausea—Tamoxifen—pancreatic cancer	0.00261	0.00393	CcSEcCtD
Trimetrexate—Fatigue—Gemcitabine—pancreatic cancer	0.0026	0.00392	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.00259	0.0039	CcSEcCtD
Trimetrexate—Nausea—Erlotinib—pancreatic cancer	0.00258	0.00388	CcSEcCtD
Trimetrexate—Feeling abnormal—Irinotecan—pancreatic cancer	0.00255	0.00384	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—RB1—pancreatic cancer	0.00255	0.00826	CbGpPWpGaD
Trimetrexate—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.00254	0.00383	CcSEcCtD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—pancreatic cancer	0.00251	0.00813	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—PPP2R5B—pancreatic cancer	0.0025	0.00811	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00248	0.00374	CcSEcCtD
Trimetrexate—Body temperature increased—Irinotecan—pancreatic cancer	0.00245	0.00369	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.00245	0.00369	CcSEcCtD
Trimetrexate—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00244	0.00368	CcSEcCtD
Trimetrexate—Anaemia—Docetaxel—pancreatic cancer	0.00242	0.00365	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.0024	0.00361	CcSEcCtD
Trimetrexate—Vomiting—Sunitinib—pancreatic cancer	0.00239	0.0036	CcSEcCtD
Trimetrexate—Body temperature increased—Gemcitabine—pancreatic cancer	0.00238	0.00359	CcSEcCtD
Trimetrexate—Neutropenia—Epirubicin—pancreatic cancer	0.00237	0.00358	CcSEcCtD
Trimetrexate—Rash—Sunitinib—pancreatic cancer	0.00237	0.00357	CcSEcCtD
Trimetrexate—Dermatitis—Sunitinib—pancreatic cancer	0.00237	0.00357	CcSEcCtD
Trimetrexate—Body temperature increased—Fluorouracil—pancreatic cancer	0.00234	0.00353	CcSEcCtD
Trimetrexate—Convulsion—Docetaxel—pancreatic cancer	0.00227	0.00342	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CCND1—pancreatic cancer	0.00227	0.00735	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—PPP2R5B—pancreatic cancer	0.00224	0.00725	CbGpPWpGaD
Trimetrexate—Nausea—Sunitinib—pancreatic cancer	0.00223	0.00336	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—FOXM1—pancreatic cancer	0.00223	0.00722	CbGpPWpGaD
Trimetrexate—Asthenia—Irinotecan—pancreatic cancer	0.00222	0.00335	CcSEcCtD
Trimetrexate—Neutropenia—Doxorubicin—pancreatic cancer	0.0022	0.00331	CcSEcCtD
Trimetrexate—Asthenia—Gemcitabine—pancreatic cancer	0.00216	0.00326	CcSEcCtD
Trimetrexate—Confusional state—Docetaxel—pancreatic cancer	0.00216	0.00325	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—RB1—pancreatic cancer	0.00215	0.00696	CbGpPWpGaD
Trimetrexate—Pruritus—Gemcitabine—pancreatic cancer	0.00213	0.00321	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—TNF—pancreatic cancer	0.00211	0.00685	CbGpPWpGaD
Trimetrexate—Pruritus—Fluorouracil—pancreatic cancer	0.0021	0.00316	CcSEcCtD
Trimetrexate—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00209	0.00316	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—MYC—pancreatic cancer	0.00209	0.00678	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—FOXM1—pancreatic cancer	0.00199	0.00646	CbGpPWpGaD
Trimetrexate—Vomiting—Irinotecan—pancreatic cancer	0.00197	0.00296	CcSEcCtD
Trimetrexate—Rash—Irinotecan—pancreatic cancer	0.00195	0.00294	CcSEcCtD
Trimetrexate—Dermatitis—Irinotecan—pancreatic cancer	0.00195	0.00294	CcSEcCtD
Trimetrexate—Vomiting—Gemcitabine—pancreatic cancer	0.00192	0.00289	CcSEcCtD
Trimetrexate—Rash—Gemcitabine—pancreatic cancer	0.0019	0.00286	CcSEcCtD
Trimetrexate—Dermatitis—Gemcitabine—pancreatic cancer	0.0019	0.00286	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—pancreatic cancer	0.00189	0.00612	CbGpPWpGaD
Trimetrexate—Vomiting—Fluorouracil—pancreatic cancer	0.00188	0.00284	CcSEcCtD
Trimetrexate—Rash—Fluorouracil—pancreatic cancer	0.00187	0.00282	CcSEcCtD
Trimetrexate—Dermatitis—Fluorouracil—pancreatic cancer	0.00187	0.00281	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—TP53—pancreatic cancer	0.00186	0.00604	CbGpPWpGaD
Trimetrexate—Fatigue—Docetaxel—pancreatic cancer	0.00184	0.00278	CcSEcCtD
Trimetrexate—Nausea—Irinotecan—pancreatic cancer	0.00184	0.00277	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—pancreatic cancer	0.00182	0.00589	CbGpPWpGaD
Trimetrexate—Nausea—Gemcitabine—pancreatic cancer	0.00179	0.0027	CcSEcCtD
Trimetrexate—Feeling abnormal—Docetaxel—pancreatic cancer	0.00176	0.00266	CcSEcCtD
Trimetrexate—Nausea—Fluorouracil—pancreatic cancer	0.00176	0.00265	CcSEcCtD
Trimetrexate—Body temperature increased—Docetaxel—pancreatic cancer	0.00169	0.00255	CcSEcCtD
Trimetrexate—Anaemia—Epirubicin—pancreatic cancer	0.00163	0.00246	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CCND1—pancreatic cancer	0.00159	0.00517	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PRSS1—pancreatic cancer	0.00156	0.00504	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ZNRF3—pancreatic cancer	0.00156	0.00504	CbGpPWpGaD
Trimetrexate—Asthenia—Docetaxel—pancreatic cancer	0.00153	0.00231	CcSEcCtD
Trimetrexate—Convulsion—Epirubicin—pancreatic cancer	0.00153	0.00231	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—MYC—pancreatic cancer	0.00152	0.00492	CbGpPWpGaD
Trimetrexate—Pruritus—Docetaxel—pancreatic cancer	0.00151	0.00228	CcSEcCtD
Trimetrexate—Anaemia—Doxorubicin—pancreatic cancer	0.00151	0.00228	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	0.00149	0.00484	CbGpPWpGaD
Trimetrexate—Confusional state—Epirubicin—pancreatic cancer	0.00145	0.00219	CcSEcCtD
Trimetrexate—Convulsion—Doxorubicin—pancreatic cancer	0.00142	0.00214	CcSEcCtD
Trimetrexate—Thrombocytopenia—Epirubicin—pancreatic cancer	0.00141	0.00213	CcSEcCtD
Trimetrexate—DHFR—Disease—DTX1—pancreatic cancer	0.00141	0.00456	CbGpPWpGaD
Trimetrexate—Vomiting—Docetaxel—pancreatic cancer	0.00136	0.00205	CcSEcCtD
Trimetrexate—Rash—Docetaxel—pancreatic cancer	0.00135	0.00203	CcSEcCtD
Trimetrexate—Dermatitis—Docetaxel—pancreatic cancer	0.00135	0.00203	CcSEcCtD
Trimetrexate—Confusional state—Doxorubicin—pancreatic cancer	0.00135	0.00203	CcSEcCtD
Trimetrexate—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.00131	0.00197	CcSEcCtD
Trimetrexate—DHFR—Metabolism—PRSS1—pancreatic cancer	0.0013	0.00422	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—MYC—pancreatic cancer	0.00128	0.00415	CbGpPWpGaD
Trimetrexate—Nausea—Docetaxel—pancreatic cancer	0.00127	0.00191	CcSEcCtD
Trimetrexate—Fatigue—Epirubicin—pancreatic cancer	0.00124	0.00187	CcSEcCtD
Trimetrexate—Feeling abnormal—Epirubicin—pancreatic cancer	0.00119	0.00179	CcSEcCtD
Trimetrexate—DHFR—Disease—DTX4—pancreatic cancer	0.00118	0.00382	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—TYMS—pancreatic cancer	0.00116	0.00377	CbGpPWpGaD
Trimetrexate—Fatigue—Doxorubicin—pancreatic cancer	0.00115	0.00173	CcSEcCtD
Trimetrexate—DHFR—Disease—PPP2R5B—pancreatic cancer	0.00115	0.00372	CbGpPWpGaD
Trimetrexate—Body temperature increased—Epirubicin—pancreatic cancer	0.00114	0.00172	CcSEcCtD
Trimetrexate—DHFR—Metabolism—ARG2—pancreatic cancer	0.00113	0.00366	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HEY2—pancreatic cancer	0.0011	0.00358	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Doxorubicin—pancreatic cancer	0.0011	0.00166	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—BRCA2—pancreatic cancer	0.00109	0.00354	CbGpPWpGaD
Trimetrexate—Body temperature increased—Doxorubicin—pancreatic cancer	0.00106	0.00159	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—TYMS—pancreatic cancer	0.00104	0.00337	CbGpPWpGaD
Trimetrexate—Asthenia—Epirubicin—pancreatic cancer	0.00104	0.00156	CcSEcCtD
Trimetrexate—DHFR—Disease—HEY1—pancreatic cancer	0.00102	0.00331	CbGpPWpGaD
Trimetrexate—Pruritus—Epirubicin—pancreatic cancer	0.00102	0.00154	CcSEcCtD
Trimetrexate—DHFR—Metabolism—TYMP—pancreatic cancer	0.000988	0.0032	CbGpPWpGaD
Trimetrexate—Asthenia—Doxorubicin—pancreatic cancer	0.000958	0.00144	CcSEcCtD
Trimetrexate—Pruritus—Doxorubicin—pancreatic cancer	0.000944	0.00142	CcSEcCtD
Trimetrexate—Vomiting—Epirubicin—pancreatic cancer	0.000917	0.00138	CcSEcCtD
Trimetrexate—Rash—Epirubicin—pancreatic cancer	0.00091	0.00137	CcSEcCtD
Trimetrexate—Dermatitis—Epirubicin—pancreatic cancer	0.000909	0.00137	CcSEcCtD
Trimetrexate—DHFR—Disease—JAG2—pancreatic cancer	0.000907	0.00294	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TERT—pancreatic cancer	0.000905	0.00293	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MEN1—pancreatic cancer	0.000894	0.0029	CbGpPWpGaD
Trimetrexate—DHFR—Disease—SLC2A2—pancreatic cancer	0.000887	0.00288	CbGpPWpGaD
Trimetrexate—Nausea—Epirubicin—pancreatic cancer	0.000857	0.00129	CcSEcCtD
Trimetrexate—DHFR—Disease—SHH—pancreatic cancer	0.000853	0.00276	CbGpPWpGaD
Trimetrexate—Vomiting—Doxorubicin—pancreatic cancer	0.000849	0.00128	CcSEcCtD
Trimetrexate—DHFR—Disease—IAPP—pancreatic cancer	0.000842	0.00273	CbGpPWpGaD
Trimetrexate—Rash—Doxorubicin—pancreatic cancer	0.000842	0.00127	CcSEcCtD
Trimetrexate—Dermatitis—Doxorubicin—pancreatic cancer	0.000841	0.00127	CcSEcCtD
Trimetrexate—DHFR—Disease—HSPA1B—pancreatic cancer	0.000808	0.00262	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GLP1R—pancreatic cancer	0.000796	0.00258	CbGpPWpGaD
Trimetrexate—Nausea—Doxorubicin—pancreatic cancer	0.000793	0.00119	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—RB1—pancreatic cancer	0.000788	0.00255	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—DPYD—pancreatic cancer	0.000783	0.00254	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SLC2A2—pancreatic cancer	0.000743	0.00241	CbGpPWpGaD
Trimetrexate—DHFR—Disease—JAG1—pancreatic cancer	0.000723	0.00234	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—RB1—pancreatic cancer	0.000704	0.00228	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	0.000692	0.00224	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CD44—pancreatic cancer	0.000687	0.00223	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HSPA1A—pancreatic cancer	0.000682	0.00221	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN2A—pancreatic cancer	0.000619	0.00201	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CCND1—pancreatic cancer	0.000585	0.0019	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CD44—pancreatic cancer	0.000576	0.00187	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GCG—pancreatic cancer	0.000552	0.00179	CbGpPWpGaD
Trimetrexate—DHFR—Disease—SMAD4—pancreatic cancer	0.000543	0.00176	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HES1—pancreatic cancer	0.00053	0.00172	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CCND1—pancreatic cancer	0.000523	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—STK11—pancreatic cancer	0.000519	0.00168	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MYC—pancreatic cancer	0.000469	0.00152	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TERT—pancreatic cancer	0.000464	0.0015	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—TYMS—pancreatic cancer	0.000446	0.00145	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HIF1A—pancreatic cancer	0.000444	0.00144	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TSC2—pancreatic cancer	0.000443	0.00144	CbGpPWpGaD
Trimetrexate—DHFR—Disease—APOE—pancreatic cancer	0.000433	0.0014	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MYC—pancreatic cancer	0.00042	0.00136	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NOTCH1—pancreatic cancer	0.0004	0.0013	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EGF—pancreatic cancer	0.000387	0.00125	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—APOE—pancreatic cancer	0.000363	0.00118	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TP53—pancreatic cancer	0.000345	0.00112	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CD—pancreatic cancer	0.000344	0.00111	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CG—pancreatic cancer	0.000328	0.00106	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PPARG—pancreatic cancer	0.000316	0.00102	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CB—pancreatic cancer	0.0003	0.000971	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PTGS2—pancreatic cancer	0.000297	0.000962	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CD—pancreatic cancer	0.000288	0.000933	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CTNNB1—pancreatic cancer	0.000266	0.000861	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PTEN—pancreatic cancer	0.000259	0.000839	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CB—pancreatic cancer	0.000251	0.000813	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PTGS2—pancreatic cancer	0.000249	0.000806	CbGpPWpGaD
Trimetrexate—DHFR—Disease—SRC—pancreatic cancer	0.00024	0.000778	CbGpPWpGaD
Trimetrexate—DHFR—Disease—STAT3—pancreatic cancer	0.000232	0.000751	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NRAS—pancreatic cancer	0.000231	0.000749	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PTEN—pancreatic cancer	0.000217	0.000703	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MYC—pancreatic cancer	0.000215	0.000698	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TGFB1—pancreatic cancer	0.000215	0.000696	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EGFR—pancreatic cancer	0.000211	0.000682	CbGpPWpGaD
Trimetrexate—DHFR—Disease—KRAS—pancreatic cancer	0.000199	0.000645	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CA—pancreatic cancer	0.000183	0.000592	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HRAS—pancreatic cancer	0.000169	0.000548	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CA—pancreatic cancer	0.000153	0.000496	CbGpPWpGaD
Trimetrexate—DHFR—Disease—AKT1—pancreatic cancer	0.000149	0.000484	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—AKT1—pancreatic cancer	0.000125	0.000405	CbGpPWpGaD
